Tarec Christoffer El‐Galaly

Also affiliated with Odense University Hospital, Aarhus University Hospital, Karolinska Institutet

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series”.

Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series

The Lancet Haematology(2025)10.1016/s2352-3026(25)00027-4

N/A

0.241DataRank · unranked

4 citations

Ajay Major, Vishal Bhatnagar, Amylou C. Dueck, Karin E. Smedby, Tarec Christoffer El‐Galaly +8 more

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00892

N/A

0.104DataRank · unranked

1 citations

Vít Procházka, Tarec Christoffer El‐Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy +43 more

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

British Journal of Haematology(2020)10.1111/bjh.16425

N/A

0DataRank · unranked

23 citations

Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob Haaber Christensen, Judit Jørgensen +19 more

Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma

American Journal of Hematology(2021)10.1002/ajh.26149

N/A

0DataRank · unranked

22 citations

Lasse Hjort Jakobsen, Raphael Mwangi, Norbert Schmitz, Umar Farooq, C. R. Flowers +18 more

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

Haematologica(2023)10.3324/haematol.2022.282411

N/A

0DataRank · unranked

17 citations

Lynda Foltz, Vikas Gupta, Robert P. Hasserjian, Taghi Manshouri, John Mascarenhas +15 more